Cipla Q1FY27: Profit falls 39%, EBITDA margin shrinks to 16.7%

Pat NegativeEbitda Margin CompressionResults View source PDF Explain this filing

CIPLA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.5%Reaction day

₹1415.90

prior close

₹1379.20

announcement price

In-mkt

timing

Nifty 100market-0.5%-0.9% vs market

Pharmaceuticals peers, median of 164sector-0.7%-0.8% vs sector

On the reaction day the stock moved 0.9 pts less than Nifty 100 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.5

15m

+0.7

30m

-0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.5-0.5-0.9-0.7-0.8

Next day

-0.5-0.9+0.4-0.8+0.4

-0.1+0.1-0.1-0.1+0.0

+2.1-0.1+2.2-0.8+2.9

+4.1+0.9+3.2+0.0+4.1

+3.7+1.2+2.5-0.6+4.3

+3.1+3.2-0.1-0.3+3.4

15d

+2.9+2.0+0.9+2.4+0.5

+1.6+1.2+0.4+0.9+0.7

-2.5-1.8-0.6+4.0-6.5

-5.5-6.4+0.9-5.5-0.0

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Cipla Q1FY27: Revenue INR 7,119 Cr, up 2% YoY. But EBITDA fell 33% to INR 1,192 Cr with margin compressing to 16.7% from 25.6%. PAT dropped 39% to INR 789 Cr. India business grew 12% YoY to a record high. North America revenue fell 21% YoY to USD 162 Mn. One Africa up 12%, Emerging Markets up 16% in INR. Net cash strong at INR 9,494 Cr.

Likely market impact

Sharp profit decline from margin compression and weak North America. India growth and strong net cash offer partial support.